Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TJ301 in Active Ulcerative Colitis Phase II Trial
CTR20180851Phase 2Completed
- Sponsor
- Leading Biopharm
- Start
- Aug 2018
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of olamkicept in autoimmune colitis, sponsored by Leading Biopharm. Started Aug 2018; status: completed.
02
Drugs
olamkicept
03
Conditions
autoimmune colitis
Beyond the preview
Go deeper on CTR20180851.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20180851.